TOUYUN BIOTECH (01332) announced its interim results for the six months ended June 30, 2025. The group recorded revenue from sales of goods and services of HK$36.581 million, representing a decrease of 20.82% year-on-year. The profit attributable to owners of the company reached HK$11.243 million, compared to a loss of HK$47.969 million in the same period last year. Earnings per share stood at HK$0.4 cents. According to the announcement, the profit was primarily attributed to increased fair value gains on financial assets measured at fair value through profit or loss.